Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
0.00 (0.00%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.47 - 1.55
52 week 1.19 - 4.42
Open 1.51
Vol / Avg. 388,009.00/931,536.00
Mkt cap 172.64M
P/E     -
Div/yield     -
EPS -0.41
Shares 121.31M
Beta 2.82
Inst. own 35%
Aug 4, 2016
Q2 2016 Idera Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 9, 2016
Q1 2016 Idera Pharmaceuticals Inc Earnings Call - Webcast
May 9, 2016
Q1 2016 Idera Pharmaceuticals Inc Earnings Release
Apr 12, 2016
Idera Pharmaceuticals Inc at Needham Healthcare Conference
Mar 14, 2016
Idera Pharmaceuticals Inc at ROTH Conference
Mar 10, 2016
Q4 2015 Idera Pharmaceuticals Inc Earnings Release
Mar 7, 2016
Idera Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4361.56% -19500.00%
Operating margin -4393.88% -19616.87%
EBITD margin - -19420.88%
Return on average assets -59.95% -67.58%
Return on average equity -65.83% -76.47%
Employees 62 -
CDP Score - -


167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Officers and directors

James A. Geraghty Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Youssef El Zein Independent Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 54
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 52
Bio & Compensation  - Reuters
Joanna C. Horobin M.D. Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Sudhir Agrawal D. Phil. Director, President of Research
Age: 61
Bio & Compensation  - Reuters
Maxine Gowen Ph.D. Director
Age: 57
Bio & Compensation  - Reuters